Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Double homeobox A pseudogene 4 (DUXAP4) is a non-protein-coding pseudogene that gives rise to a long non-coding RNA. DUXAP4 lncRNA is overexpressed in several cancers, including colorectal and non-small cell lung cancer, where it promotes tumor cell proliferation, inhibits apoptosis, and advances tumor progression. DUXAP4 exerts its oncogenic properties primarily through interactions with chromatin-modifying proteins such as LSD1 and EZH2, leading to the epigenetic repression of tumor suppressor genes, including p21 and PTEN. DUXAP4 does not encode a functional protein or act as a classical receptor, enzyme, or therapeutic drug target; rather, it acts through its RNA product to modulate gene expression and cancer phenotypes. Overexpression of DUXAP4 in tumors may serve as a prognostic biomarker but, as of now, is not directly targeted by any drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Double homeobox A pseudogene 4 (DUXAP4).